Sleepless from the Get Go: Sleep Problems Prior to Initiating Cancer Treatment

Zhou, Eric S.; Clark, Karen; Recklitis, Christopher J.; Obenchain, Richard; Loscalzo, Matthew

doi:10.1007/s12529-018-9715-2

Cited by 17 publications

(15 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sleep problems (experienced between 12.5% and 56%) is one of the most prevalent symptom in cancer patients and survivors [5,7,11]. The possible causes of this wide range of prevalence may be due to demographic variables such as age, type of tumor, and type of treatment [6,11]. Sleep problems together with depression predicted poor QoL in colorectal patients, the largest group in this series [7].…”

Section: Discussionmentioning

confidence: 83%

“…This study examines sleep problems in cancer patients who will initiate adjuvant chemotherapy and confirms its high prevalence in both women and men, 65.5% and 51.1%, respectively. Sleep problems (experienced between 12.5% and 56%) is one of the most prevalent symptom in cancer patients and survivors [5,7,11]. The possible causes of this wide range of prevalence may be due to demographic variables such as age, type of tumor, and type of treatment [6,11].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence of sleep problems and their mediating role on depression and anxious preoccupation in patients with resected, non-advanced cancer: data from NEOcoping study

et al. 2019

View full text Add to dashboard Cite

Background Our study analyzes the incidence of sleep problems and their mediating role on depression and anxious preoccupation in patients with resected, non-advanced cancer. Methods A multi-institutional, prospective, observational study was conducted with 750 participants of 14 hospitals in Spain. Participants' socio-demographic and clinical characteristics were collected using a standardized self-report form and using EORTC QoL-QLQ-C30, BSI, Mini-MAC questionnaires. Results In women, sleep problems, depression and anxious preoccupation were observed in 65, 41 and 21%, respectively. In men, sleep problems, depression and anxious preoccupation were reported in 51, 29 and 61%, respectively. More sleep problems, depression and anxious preoccupation were found among women than males. Depression was a significant predictor of anxious preoccupation. In males, sleep problems partially mediated this association. This was not confirmed in women. Conclusion Our findings point toward the importance of developing interventions that decrease depression and sleep problems in cancer.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Incidence of sleep problems and their mediating role on depression and anxious preoccupation in patients with resected, non-advanced cancer: data from NEOcoping study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In addition to physical complaints, especially psychological distress is a big challenge for patients. In particular, in the immediate period after diagnosis, patients experience a high burden, to which they can respond with different stress symptoms [15][16][17].…”

Section: Discussionmentioning

confidence: 99%

Quality of Patient Information by Urologists Is Associated with Mental Distress in Bladder Cancer Patients

et al. 2020

View full text Add to dashboard Cite

Aims:The study aimed to evaluate the prevalence of mental distress in patients with newly diagnosed bladder cancer, the cancer-information search behavior, and the influence of information seeking on distress. Methods: One hundred and one bladder cancer patients answered 2 established questionnaires ("Hospital Anxiety and Depression Scale" [HADS] and the "Fragebogen zur Belastung von Krebskranken" [FBK-R23]) for evaluation of mental distress and a self-developed questionnaire with questions concerning information seeking and socioeconomic facts. Results: Regarding risk group stratification, 57.4% were classified as high-risk and 42.6% as low-risk tumor-bearing patients. Analysis of mental distress showed that 23.2% had a score above the HADS-A cutoff, 25.3% above the HADS-D cutoff, and 21.4% showed a pathologic FBK-R23 score. Overall, 75% felt well informed about their illness. Risk group stratification did not correlate with HADS-A, HADS-D, or FBK-R23 score. Furthermore, active search for information or the use of the Internet did not cor-relate with the HADS-A, HADS-D, or FBK-R23 score. However, the quality of the urologist's information and the feeling of being informed correlated with the grade of mental distress. Conclusion: Besides the treatment of bladder cancer, informing the patient about the disease in a psychologically wholesome manner and working together with psycho-oncologically trained psychologists are essential tasks for the treating urologist.

show abstract

“…Novel therapies aimed to treat cancer by using histone methylation drugs show positive results (Harb-de la Rosa et al, 2015; Pleyer and Greil, 2015; Castilho et al, 2017; Choi et al, 2017; Curry et al, 2018). It would be interesting to determine whether using DZNep may control sleepiness in patients with cancer or if GSK-J1 might modulate insomnia caused by stress prior to undergoing radiotherapy (Davies et al, 2017; Vin-Raviv et al, 2017; Miladinia et al, 2018; Zhou et al, 2018). Testing this hypothesis in experimental models of sleep disturbances would give us an important comprehensive insight of the role of histone methylation/demethylation in the management of sleep disturbances.…”

Section: Discussionmentioning

confidence: 99%

Sleep and Neurochemical Modulation by DZNep and GSK-J1: Potential Link With Histone Methylation Status

et al. 2019

View full text Add to dashboard Cite

Histone methylation/demethylation plays an important modulatory role in chromatin restructuring, RNA transcription and is essential for controlling a plethora of biological processes. Due to many human diseases have been related to histone methylation/demethylation, several compounds such as 3-deazaneplanocin A (DZNep) or 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-Alanine (GSK-J1), have been designed to inhibit histone methylase or suppress histone demethylase, respectively. In the present study, we investigated the effects on the sleep-wake cycle and sleep-related neurochemical levels after systemic injections of DZNep or GSK-J1 given during the light or dark phase in rats. DZNep dose-dependently (0.1, 1.0, or 10 mg/kg, i.p.) prolonged wakefulness (W) duration while decreased slow wave sleep (SWS) and rapid eye movement sleep (REMS) time spent during the lights-on period with no changes observed in dark phase. In opposite direction, GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.) injected at the beginning of the lights-on period induced no statistical changes in W, SWS, or REMS whereas if administered at darkness, we found a diminution in W and an enhancement in SWS and REMS. Finally, brain microdialysis experiments in freely moving animals were used to evaluate the effects of DZNep or GSK-J1 treatments on contents of sleep-related neurochemicals. The results showed that DZNep boosted extracellular levels of dopamine, norepinephrine, epinephrine, serotonin, adenosine, and acetylcholine if injected at the beginning of the lights-on period whereas GSK-J1 exerted similar outcomes but when administered at darkness. In summary, DZNep and GSK-J1 may control the sleep-wake cycle and sleep-related neurochemicals through histone methylation/demethylation activity.

show abstract

Sleepless from the Get Go: Sleep Problems Prior to Initiating Cancer Treatment

Cited by 17 publications

References 69 publications

Incidence of sleep problems and their mediating role on depression and anxious preoccupation in patients with resected, non-advanced cancer: data from NEOcoping study

Incidence of sleep problems and their mediating role on depression and anxious preoccupation in patients with resected, non-advanced cancer: data from NEOcoping study

Quality of Patient Information by Urologists Is Associated with Mental Distress in Bladder Cancer Patients

Sleep and Neurochemical Modulation by DZNep and GSK-J1: Potential Link With Histone Methylation Status

Contact Info

Product

Resources

About